Center for Stem Cell and Tissue Engineering, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Stem Cells Dev. 2013 Jan 1;22(1):90-101. doi: 10.1089/scd.2012.0116. Epub 2012 Aug 14.
Immunological response hampers the investigation of human embryonic stem cells (hESCs) or their derivates for tissue regeneration in vivo. Immunosuppression is often used after surgery, but exhibits side effects of significant weight loss and allows only short-term observation. The purpose of this study was to investigate whether neonatal desensitization supports relative long-term survival of hESC-derived mesenchymal stem cells (hESC-MSCs) and promotes cartilage regeneration. hESC-MSCs were injected on the day of birth in rats. Six weeks after neonatal injection, a full-thickness cylindrical cartilage defect was created and transplanted with a hESC-MSC-seeded collagen bilayer scaffold (group d+s+c) or a collagen bilayer scaffold (group d+s). Rats without neonatal injection were transplanted with the hESC-MSC-seeded collagen bilayer scaffold to serve as controls (group s+c). Cartilage regeneration was evaluated by histological analysis, immunohistochemical staining, and biomechanical test. The role of hESC-MSCs in cartilage regeneration was analyzed by CD4 immunostaining, cell death detection, and visualization of human cells in regenerated tissues. hESC-MSCs expressed CD105, CD73, CD90, CD29, and CD44, but not CD45 and CD34, and possessed trilineage differentiation potential. Group d+s+c exhibited greater International Cartilage Repair Society (ICRS) scores than group d+s or group s+c. Abundant collagen type II and improved mechanical properties were detected in group d+s+c. There were less CD4+ inflammatory cell infiltration and cell death at week 1, and hESC-MSCs were found to survive as long as 8 weeks after transplantation in group d+s+c. Our study suggests that neonatal desensitization before transplantation may be an efficient way to develop a powerful tool for preclinical study of human cell-based therapies in animal models.
免疫反应阻碍了对人类胚胎干细胞(hESC)或其衍生物在体内进行组织再生的研究。手术后通常会使用免疫抑制,但会产生显著体重减轻的副作用,并且只能进行短期观察。本研究旨在探讨新生儿脱敏是否支持 hESC 衍生的间充质干细胞(hESC-MSC)的相对长期存活,并促进软骨再生。在大鼠出生当天注射 hESC-MSC。新生儿注射后 6 周,创建全层圆柱形软骨缺损,并移植 hESC-MSC 接种胶原双层支架(组 d+s+c)或胶原双层支架(组 d+s)。未进行新生儿注射的大鼠移植 hESC-MSC 接种胶原双层支架作为对照(组 s+c)。通过组织学分析、免疫组织化学染色和生物力学测试评估软骨再生。通过 CD4 免疫染色、细胞死亡检测和再生组织中人类细胞的可视化分析 hESC-MSCs 在软骨再生中的作用。hESC-MSCs 表达 CD105、CD73、CD90、CD29 和 CD44,但不表达 CD45 和 CD34,并具有三系分化潜能。组 d+s+c 的国际软骨修复学会(ICRS)评分高于组 d+s 或组 s+c。组 d+s+c 中检测到丰富的 II 型胶原和改善的机械性能。在第 1 周时,CD4+炎症细胞浸润和细胞死亡较少,在组 d+s+c 中发现 hESC-MSCs 可存活长达 8 周。我们的研究表明,移植前的新生儿脱敏可能是一种有效的方法,可以为动物模型中人类细胞治疗的临床前研究开发强大的工具。